{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:48:39Z","timestamp":1764078519633},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1053\/j.seminoncol.2004.04.002","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"27-34","source":"Crossref","is-referenced-by-count":36,"special_numbering":"S8","title":["Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia"],"prefix":"10.1053","volume":"31","author":[{"given":"Laura","family":"Biganzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Skacel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Luis","family":"Pico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.04.002_BIB1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","article-title":"Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"16","author":"Gomez","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB2","first-page":"349a","article-title":"Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy","volume":"20","author":"Lyman","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB3","unstructured":"National Cancer Institute: Common Toxicity Criteria. Available at: http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf (accessed December 12, 2003)"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB4","series-title":"Cancer","first-page":"2659","article-title":"Infections in the cancer patient","author":"Freifeld","year":"1997"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00062752-200205000-00006","article-title":"Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients","volume":"9","author":"Lyman","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.04.002_BIB7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","article-title":"Colony-stimulating factors for the management of neutropenia in cancer patients","volume":"62","author":"Dale","year":"2002","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB8","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.04.002_BIB9","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1592\/phco.20.10.104S.35232","article-title":"A predictive model for neutropenia associated with cancer chemotherapy","volume":"20","author":"Lyman","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2000.18.7.1412","article-title":"Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen in elderly patients with breast cancer","volume":"18","author":"Crivellari","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB13","first-page":"207","article-title":"Murine granulocyte colony-stimulating factor","volume":"83","author":"Nicola","year":"1988","journal-title":"Behring Inst Mitt"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29a","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000227575","article-title":"Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer","volume":"53","author":"de Graaf","year":"1996","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma","volume":"80","author":"Pettengell","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0959-8049(97)00222-0","article-title":"A European perspective on haematopoietic growth factors in haemato-oncology","volume":"33","author":"Croockewit","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1023\/A:1012468723966","article-title":"ESMO recommendations for the application of haematopoietic growth factors","volume":"12","year":"2001","journal-title":"Ann Oncol"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.04.002_BIB20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0093-7754(03)00312-9","article-title":"Balancing the benefits and costs of colony-stimulating factors","volume":"30","author":"Lyman","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2001.19.5.1583","article-title":"Patients aged \u226570 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy","volume":"19","author":"Balducci","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB22","first-page":"221","article-title":"General guidelines for the management of older patients with cancer","volume":"14","author":"Balducci","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB23","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0959-8049(03)00662-2","article-title":"EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer","volume":"39","author":"Repetto","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008271804151","article-title":"The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy","volume":"8","author":"Crawford","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB25","first-page":"249","article-title":"The uses and properties of PEG-linked proteins","volume":"9","author":"Delgado","year":"1992","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.04.002_BIB26","first-page":"379a","article-title":"Filgrastim-SD a sustained duration form of filgrastim (rhuG-CSF) has similar effects on neutrophil function compared to filgrastim","volume":"92","author":"McKenna","year":"1998","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.04.002_BIB27","first-page":"172b","article-title":"Phase I study comparing daily filgrastim and single dose sustained-duration filgrastim (SD\/01) in normal volunteers","volume":"94","author":"Allen","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB28","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2000.18.13.2522","article-title":"Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy","volume":"18","author":"Johnston","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB30","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(88)91475-4","article-title":"Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy","volume":"1","author":"Morstyn","year":"1988","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB32","first-page":"157b","article-title":"Pharmacokinetic rationale for a fixed-dose regimen of a sustained-duration form of filgrastim in cancer patients","volume":"96","author":"Yang","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.thj.6200023","article-title":"Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor","volume":"1","author":"Mukae","year":"2000","journal-title":"Hematol J"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB36","first-page":"715","article-title":"A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer","volume":"10","author":"Siena","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB38","first-page":"69a","article-title":"Bone pain with pegfilgrastim is similar to that seen with filgrastim","volume":"21","author":"Kubista","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 8","key":"10.1053\/j.seminoncol.2004.04.002_BIB39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2004.04.004","article-title":"Dose-dense chemotherapy in breast cancer and lymphoma","volume":"31","author":"Hudis","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB40","first-page":"641a","article-title":"A single pegfilgrastim dose-per-cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkin\u2019s lymphoma","volume":"102","author":"Moore","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB41","first-page":"637a","article-title":"Single administration of a fixed dose pegfilgrastim (Neulasta) in inducing neutrophil count recovery after 170 consecutive doses of ABVD chemotherapy in patients with Hodgkin lymphoma","volume":"102","author":"Younes","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.04.002_BIB42","first-page":"524a","article-title":"Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis","volume":"102","author":"Yang","year":"2003","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:03:40Z","timestamp":1586538220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404001964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":42,"alternative-id":["S0093775404001964"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.04.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}